{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:04:42Z","timestamp":1780347882766,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 82201556"],"award-info":[{"award-number":["Grant No. 82201556"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13267-x","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:57:58Z","timestamp":1753725478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-4928","authenticated-orcid":false,"given":"Ying","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-5930","authenticated-orcid":false,"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-0421","authenticated-orcid":false,"given":"Tingjun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7563-6957","authenticated-orcid":false,"given":"Lining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-5184","authenticated-orcid":false,"given":"Chuanzhu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3431","authenticated-orcid":false,"given":"Qinzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"1","key":"13267_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"13267_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"4","key":"13267_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102498","volume":"19","author":"M Garibaldi","year":"2020","unstructured":"Garibaldi M, Fionda L, Vanoli F, Leonardi L, Loreti S, Bucci E et al (2020) Muscle involvement in myasthenia gravis: expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients. Autoimmun Rev 19(4):102498","journal-title":"Autoimmun Rev"},{"issue":"2","key":"13267_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000535","volume":"6","author":"N Uchio","year":"2019","unstructured":"Uchio N, Taira K, Ikenaga C, Kadoya M, Unuma A, Yoshida K et al (2019) Inflammatory myopathy with myasthenia gravis: thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm 6(2):e535","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"13267_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.semarthrit.2018.05.004","volume":"48","author":"K Huang","year":"2019","unstructured":"Huang K, Shojania K, Chapman K, Amiri N, Dehghan N, Mezei M (2019) Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: a case series and literature review. Semin Arthritis Rheum 48(4):745\u2013751","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"13267_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.autrev.2017.04.009","volume":"16","author":"E Santos","year":"2017","unstructured":"Santos E, Coutinho E, Martins da Silva A, Marinho A, Vasconcelos C, Taipa R et al (2017) Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: report of four cases and literature review. Autoimmun Rev 16(6):644\u2013649","journal-title":"Autoimmun Rev"},{"issue":"6","key":"13267_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.semarthrit.2013.12.005","volume":"43","author":"JJ Paik","year":"2014","unstructured":"Paik JJ, Corse AM, Mammen AL (2014) The co-existence of myasthenia gravis in patients with myositis: a case series. Semin Arthritis Rheum 43(6):792\u2013796","journal-title":"Semin Arthritis Rheum"},{"key":"13267_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072449","author":"M Kozak","year":"2025","unstructured":"Kozak M, Kovacs E, Nagy-Vince M, Toth A, Boczan J (2025) Prevalence of elevated CK levels, myositis-specific and myositis-associated antibodies, myositis, and other neuromuscular diseases in myasthenia gravis patients-experience from an Eastern European tertiary center. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14072449","journal-title":"J Clin Med"},{"issue":"1","key":"13267_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","volume":"21","author":"NA Allameen","year":"2025","unstructured":"Allameen NA, Ramos-Lisbona AI, Wedderburn LR, Lundberg IE, Isenberg DA (2025) An update on autoantibodies in the idiopathic inflammatory myopathies. Nat Rev Rheumatol 21(1):46\u201362","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"13267_CR10","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","volume":"9","author":"K Kufukihara","year":"2019","unstructured":"Kufukihara K, Watanabe Y, Inagaki T, Takamatsu K, Nakane S, Nakahara J et al (2019) Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis. Sci Rep 9(1):5284","journal-title":"Sci Rep"},{"issue":"2","key":"13267_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0022-510X(78)90060-6","volume":"38","author":"C Vasilescu","year":"1978","unstructured":"Vasilescu C, Bucur G, Petrovici A, Florescu A (1978) Myasthenia in patients with dermatomyositis: clinical, electrophysiological and ultrastructural studies. J Neurol Sci 38(2):129\u2013144","journal-title":"J Neurol Sci"},{"issue":"11","key":"13267_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"S Suzuki","year":"2009","unstructured":"Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K et al (2009) Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66(11):1334\u20131338","journal-title":"Arch Neurol"},{"key":"13267_CR13","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC international workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord 2018;28(1):87\u201399.","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"13267_CR14","doi-asserted-by":"crossref","unstructured":"Mammen AL, Allenbach Y, Stenzel W, Benveniste O, ENMC 239th Workshop Study Group. 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscul Disord 2020;30(1):70\u201392.","DOI":"10.1016\/j.nmd.2019.10.005"},{"issue":"5","key":"13267_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14(5):337\u2013345","journal-title":"Neuromuscul Disord"},{"key":"13267_CR16","doi-asserted-by":"crossref","unstructured":"Rose MR, ENMC IBM Working Group. 188th ENMC international workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23(12):1044\u201355.","DOI":"10.1016\/j.nmd.2013.08.007"},{"issue":"10","key":"13267_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"2","key":"13267_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140(2):80\u201391","journal-title":"Circulation"},{"issue":"5","key":"13267_CR19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76(5):792\u2013801","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"13267_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","volume":"72","author":"CD Kassardjian","year":"2015","unstructured":"Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M (2015) Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 72(9):996\u20131003","journal-title":"JAMA Neurol"},{"key":"13267_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13319","volume":"35","author":"B Zhao","year":"2024","unstructured":"Zhao B, Hou Y, Shao K, Ma X, Yan Y, Lu JQ et al (2024) Clinico-sero-pathological characteristics of anti-Ha antisynthetase syndrome. Brain Pathol 35:e13319","journal-title":"Brain Pathol"},{"issue":"7","key":"13267_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/art.23012","volume":"57","author":"LR Wedderburn","year":"2007","unstructured":"Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B et al (2007) International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 57(7):1192\u20131201","journal-title":"Arthritis Rheum"},{"issue":"7","key":"13267_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"issue":"9","key":"13267_CR24","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L et al (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol 271(9):6209\u20136219","journal-title":"J Neurol"},{"issue":"6","key":"13267_CR25","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I, Kolb H, Regev K, Schwartzmann Y et al (2024) Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol 271(6):3462\u20133470","journal-title":"J Neurol"},{"issue":"12","key":"13267_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O (2020) Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16(12):689\u2013701","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"13267_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","volume":"58","author":"AM Yamamoto","year":"2001","unstructured":"Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L et al (2001) Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 58(6):885\u2013890","journal-title":"Arch Neurol"},{"issue":"5","key":"13267_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis \u2013 autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12(5):259\u2013268","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"13267_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/art.43038","volume":"77","author":"S Faghihi-Kashani","year":"2025","unstructured":"Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A et al (2025) Clinical characteristics of anti-synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome project. Arthritis Rheumatol 77(4):477\u2013489","journal-title":"Arthritis Rheumatol"},{"key":"13267_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S et al (2025) Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur 50:101192","journal-title":"Lancet Reg Health Eur"},{"key":"13267_CR31","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B et al (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClin Med 70:102536","journal-title":"EClin Med"},{"issue":"9","key":"13267_CR32","first-page":"518","volume":"31","author":"JM Weaver","year":"2023","unstructured":"Weaver JM, Dodd K, Knight T, Chaudhri M, Khera R, Lilleker JB et al (2023) Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series. Support Care Cancer 31(9):518","journal-title":"Support Care Cancer"},{"key":"13267_CR33","doi-asserted-by":"publisher","first-page":"1597259","DOI":"10.3389\/fimmu.2025.1597259","volume":"16","author":"A Sanchez-Camacho","year":"2025","unstructured":"Sanchez-Camacho A, Torres-Zurita A, Gallego-Lopez L, Hernandez-Pacheco R, Silva-Romeiro S, Alamo de la Gala MDC et al (2025) Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol 16:1597259","journal-title":"Front Immunol"},{"issue":"12","key":"13267_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052\u20131061","journal-title":"Oncologist"},{"issue":"1","key":"13267_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2990.2008.00965.x","volume":"35","author":"S Martignago","year":"2009","unstructured":"Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C (2009) Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 35(1):103\u2013110","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"13267_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00415-010-5823-x","volume":"258","author":"G Cenacchi","year":"2011","unstructured":"Cenacchi G, Papa V, Fanin M, Pegoraro E, Angelini C (2011) Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies. J Neurol 258(5):746\u2013752","journal-title":"J Neurol"},{"issue":"3","key":"13267_CR37","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J et al (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94(3):e299\u2013e313","journal-title":"Neurology"},{"key":"13267_CR38","doi-asserted-by":"publisher","first-page":"175628642412267","DOI":"10.1177\/17562864241226745","volume":"17","author":"Y Wang","year":"2024","unstructured":"Wang Y, Huan X, Zhu X, Song J, Yan C, Yang L et al (2024) Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study. Ther Adv Neurol Disord 17:17562864241226744","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"13267_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M et al (2023) Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 94(6):467\u2013473","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"13267_CR40","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L, Briand E, Jaworski T, Roussel G et al (2023) Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford) 62(12):4006\u20134011","journal-title":"Rheumatology (Oxford)"},{"key":"13267_CR41","doi-asserted-by":"publisher","first-page":"1447182","DOI":"10.3389\/fimmu.2024.1447182","volume":"15","author":"M Yang","year":"2024","unstructured":"Yang M, Yuan J, Wang Y, Hao H, Zhang W, Wang Z et al (2024) Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod. Front Immunol 15:1447182","journal-title":"Front Immunol"},{"key":"13267_CR42","doi-asserted-by":"publisher","first-page":"1495415","DOI":"10.3389\/fimmu.2024.1495415","volume":"15","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Chen K, Zeng L, Xu L, Tan S (2024) Case report: rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod. Front Immunol 15:1495415","journal-title":"Front Immunol"},{"key":"13267_CR43","doi-asserted-by":"publisher","first-page":"1560483","DOI":"10.3389\/fneur.2025.1560483","volume":"16","author":"Q Peng","year":"2025","unstructured":"Peng Q, Yao X, Chen S, Li X, Lin F, Zou Z (2025) Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy. Front Neurol 16:1560483","journal-title":"Front Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13267-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:36:52Z","timestamp":1757309812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13267-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13267"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13267-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no financial conflict of interests for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committee of Qilu Hospital (Qingdao), Shandong University, China (Approval no. KYLL-KS-2022054).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"542"}}